Lipoprotein(a), homocysteine and coronary atherosclerosis in young and middle-aged men
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Aim. To investigate the association between serum homocysteine, lipoprotein(a) (Lp(a)) and coronary atherosclerosis in young and middle-aged men.
Material and methods. The study included 40 men aged 29-58 years (mean age 43,8±6,2 years), with coronary heart disease (CHD) verified by coronary angiography. The control group (CG) included 27 CHD-free men. In all participants, concentrations of homocysteine, Lp(a), total cholesterol (TCH), triglycerides (TG), high-density lipoprotein CH (HDL-CH) were assessed. Low-density lipoprotein CH (LDL-CH) level was calculated using Friedewald formula.
Results. Concentrations of homocysteine, Lp(a), TCH, and LDL-CH were significantly higher in CHD patients than in CG individuals: 12,4±5,8 and 10,0±2,9 micromol/l (p<0,05); 37±40 and 13±11 mg/dl (p<0,01); 6,4±1,3 and 5,6±1,0 mmol/l (p<0,01); 4,4±1,2 and 3,4±0,9 mmol/l (p<0,001), respectively. No significant inter-group differences in TG and HDL-CH levels were observed. In multiple regression analysis, coronary atherosclerosis presence and severity was independently associated with Lp(a), but not with homocysteine level. There was a positive correlation between Lp(a) and homocysteine concentrations.
Conclusion. In young and middle-aged men, coronary atherosclerosis was associated with increased Lp(a) level, being unassociated with homocysteine concentration.About the Authors
M. V. EzhovRussian Federation
E. P. Trukhacheva
Russian Federation
O. I. Afanasyeva
Russian Federation
M. I. Afanasyeva
Russian Federation
A. A. Kambegova
Russian Federation
A. A. Lyakishev
Russian Federation
S. N. Pokrovsky
Russian Federation
References
1. Linde R, Linde B. Lipids and risk assessment. Cardiol Rev 2001;9: 348-58.
2. Evans RW, Shaten BJ, Hempel JD, et al. Homocyst (e) ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
3. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
4. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
5. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-7.
6. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report Ateroskleroz Kardiovaskulyarnaya terapiya i profilaktika, 2008; 7(5) 15 Postupila 18/04-2008 of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: Recent Advances and Future Directions Clinical Chemistry 2003; 49: 1785-96.
7. MacLean JW, Tomlinson JE, Kuang WJ, et al. cDNA Sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.
8. Foody JM, Milberg JA, Robinson K, et al. Homocysteine and lipoprotein (a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-9.
9. Hopkins PN, Wu LL, Hunt SC, et al. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783- 92.
10. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst (e) inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
11. Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103: 3062-8.
12. Harris M, Shammas NW, Jerin M. Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein (a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Prev Cardiol 2004; 7: 106-8.
13. Pokrovsky SN, Ezhov MV, Il`ina LN, et al. Association of lipoprotein (a) excess with early vein graft occlusions in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 126/4: 1071-5.
14. Vrentzos G, Papadakis JA, Malliaraki N, et al. Association of serum total homocysteine with the extent of ischemic heart disease in a Mediterranean cohort. Angiology 2004; 55(5): 517-24.
15. Ogawa M, Abe S, Saigo M, et al. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res 2003; 109(5-6): 253-8.
16. Herrmann W, Stanger O, Knapp JP, et al. Post-methionineload hyperhomocysteinemia and increased lipoprotein (a) are associated with renal metabolic dysfunction: a hypothesis. Metabolism 2002; 51(10): 1235-40.
17. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-15.
18. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein (a) assembly: a study of wild-type and mutant apolipoprotein (a) phenotypes isolated from human and rhesus monkey lipoprotein (a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.
19. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567-77.
20. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
21. Seed M, O’Connor B, Perombelon N, et al. The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101: 61-8.
Review
For citations:
Ezhov M.V., Trukhacheva E.P., Afanasyeva O.I., Afanasyeva M.I., Kambegova A.A., Lyakishev A.A., Pokrovsky S.N. Lipoprotein(a), homocysteine and coronary atherosclerosis in young and middle-aged men. Cardiovascular Therapy and Prevention. 2008;7(5):11-15. (In Russ.)
ISSN 2619-0125 (Online)